{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:13:34Z","timestamp":1780665214234,"version":"3.54.1"},"reference-count":207,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bbrc.2026.154003","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:18:53Z","timestamp":1779319133000},"page":"154003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Leveraging CRISPR\/Cas9 for optimized adoptive T cell therapies: From molecular engineering to clinical manufacturing"],"prefix":"10.1016","volume":"826","author":[{"given":"Ji-Hyeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2913-9723","authenticated-orcid":false,"given":"Hyang-Mi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.154003_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.bbrc.2026.154003_bib2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2026.154003_bib3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2026.154003_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40164-024-00504-8","article-title":"Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy","volume":"13","author":"Shao","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2026.154003_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40164-022-00291-0","article-title":"TCR engineered T cells for solid tumor immunotherapy","volume":"11","author":"Zhang","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2026.154003_bib6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.bbrc.2026.154003_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2026.154003_bib8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","article-title":"Reprogramming human T cell function and specificity with non-viral genome targeting","volume":"559","author":"Roth","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154003_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2026.154003_bib10","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2026.154003_bib11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154003_bib12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 therapeutics: progress and prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.bbrc.2026.154003_bib13","first-page":"353","article-title":"Mechanism and applications of CRISPR\/Cas-9-Mediated genome editing","volume":"15","author":"Asmamaw","year":"2021","journal-title":"Biologics"},{"key":"10.1016\/j.bbrc.2026.154003_bib14","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s13238-017-0410-x","article-title":"Advancing chimeric antigen receptor T cell therapy with CRISPR\/Cas9","volume":"8","author":"Ren","year":"2017","journal-title":"Protein Cell"},{"key":"10.1016\/j.bbrc.2026.154003_bib15","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.tig.2021.02.008","article-title":"DNA repair pathway choices in CRISPR-Cas9-Mediated genome editing","volume":"37","author":"Xue","year":"2021","journal-title":"Trends Genet."},{"key":"10.1016\/j.bbrc.2026.154003_bib16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s11658-024-00561-1","article-title":"CRISPR-Cas9 applications in T cells and adoptive T cell therapies","volume":"29","author":"Chen","year":"2024","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.bbrc.2026.154003_bib17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.imlet.2022.03.005","article-title":"CRISPR\/Cas-based human T cell engineering: basic research and clinical application","volume":"245","author":"Bernard","year":"2022","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.bbrc.2026.154003_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16030346","article-title":"CRISPR\/Cas9-Mediated customizing strategies for adoptive T-Cell therapy","volume":"16","author":"Park","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbrc.2026.154003_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.835762","article-title":"Cancer therapy with TCR-Engineered T cells: current strategies, challenges, and prospects","volume":"13","author":"Shafer","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.154003_bib20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s13046-021-02076-5","article-title":"CRISPR\/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy","volume":"40","author":"Ghaffari","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154003_bib21","article-title":"Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy","volume":"2","author":"Muller","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bbrc.2026.154003_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.101031","article-title":"Orthotopic T-cell receptor replacement in primary human T cells using CRISPR-Cas9-mediated homology-directed repair","volume":"3","author":"Moosmann","year":"2022","journal-title":"STAR Protoc."},{"key":"10.1016\/j.bbrc.2026.154003_bib23","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bbrc.2026.154003_bib24","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.molcel.2021.12.026","article-title":"CRISPR-based genome editing through the lens of DNA repair","volume":"82","author":"Nambiar","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbrc.2026.154003_bib25","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","article-title":"Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression","volume":"152","author":"Qi","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2026.154003_bib26","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2013.06.044","article-title":"CRISPR-Mediated modular RNA-Guided regulation of transcription in eukaryotes","volume":"154","author":"Gilbert","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2026.154003_bib27","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nmeth.3312","article-title":"Highly efficient Cas9-mediated transcriptional programming","volume":"12","author":"Chavez","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.bbrc.2026.154003_bib28","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbrc.2026.154003_bib29","doi-asserted-by":"crossref","first-page":"7208","DOI":"10.1038\/s41467-025-62606-z","article-title":"The hidden risks of CRISPR\/Cas: structural variations and genome integrity","volume":"16","author":"Aussel","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154003_bib30","doi-asserted-by":"crossref","first-page":"471","DOI":"10.6026\/97320630018471","article-title":"From design to validation of CRISPR\/gRNA primers towards genome editing","volume":"18","author":"Jamee","year":"2022","journal-title":"Bioinformation"},{"key":"10.1016\/j.bbrc.2026.154003_bib31","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154003_bib32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154003_bib33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154003_bib34","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41467-023-35886-6","article-title":"Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing","volume":"14","author":"Tao","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154003_bib35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nm.4015","article-title":"Prospects for gene-engineered T cell immunotherapy for solid cancers","volume":"22","author":"Klebanoff","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2026.154003_bib36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3389\/fimmu.2013.00371","article-title":"Antigen-Specific T-Cell activation independently of the MHC: chimeric antigen receptor-redirected T cells","volume":"4","author":"Chmielewski","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.154003_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1621812","article-title":"The tumor immune microenvironment: implications for cancer immunotherapy, treatment strategies, and monitoring approaches","volume":"16","author":"Racacho","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.154003_bib38","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.21037\/tcr-23-2044","article-title":"The role of CD4(+) CAR T cells in cancer immunotherapy","volume":"13","author":"Bove","year":"2024","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154003_bib39","article-title":"TCR-T immunotherapy: the challenges and solutions","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2026.154003_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adu5754","article-title":"Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer","volume":"11","author":"Saillard","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbrc.2026.154003_bib41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev-immunol-090222-110914","volume":"42","author":"Baessler","year":"2024","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2026.154003_bib42","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2026.154003_bib43","article-title":"Tumor microenvironment immunosuppression: a roadblock to CAR T-Cell advancement in solid tumors","volume":"11","author":"Johnson","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bbrc.2026.154003_bib44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-025-01744-9","article-title":"Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?","volume":"18","author":"Vo","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2026.154003_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111239","article-title":"The persistence and antitumor efficacy of CAR-T cells are modulated by tonic signaling within the CDR","volume":"126","author":"Zhou","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbrc.2026.154003_bib46","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-023-01504-7","article-title":"Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy","volume":"16","author":"Bulliard","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2026.154003_bib47","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.stem.2023.02.009","article-title":"Advancing cell-based cancer immunotherapy through stem cell engineering","volume":"30","author":"Li","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bbrc.2026.154003_bib48","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.154003_bib49","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2026.154003_bib50","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbrc.2026.154003_bib51","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J. Immunother."},{"key":"10.1016\/j.bbrc.2026.154003_bib52","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J."},{"key":"10.1016\/j.bbrc.2026.154003_bib53","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.154003_bib54","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40164-025-00654-3","article-title":"Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer","volume":"14","author":"Lyu","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2026.154003_bib55","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2026.154003_bib56","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41375-024-02444-y","article-title":"Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy","volume":"38","author":"Lei","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2026.154003_bib57","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-025-01745-8","article-title":"Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies","volume":"18","author":"Su","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2026.154003_bib58","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.omto.2022.01.004","article-title":"Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy","volume":"24","author":"Chamberlain","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.bbrc.2026.154003_bib59","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2026.154003_bib60","article-title":"Reprogramming of IL-12 secretion in the PDCD1 locus improves the anti-tumor activity of NY-ESO-1 TCR-T cells","volume":"14","author":"Kim","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.154003_bib61","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","article-title":"Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors","volume":"18","author":"Wang","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bbrc.2026.154003_bib62","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","article-title":"Non-viral precision T cell receptor replacement for personalized cell therapy","volume":"615","author":"Foy","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154003_bib63","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2026.154003_bib64","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.bbrc.2026.154003_bib65","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","article-title":"De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation","volume":"170","author":"Ghoneim","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2026.154003_bib66","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.cell.2019.07.044","article-title":"Systematic immunotherapy target discovery using genome-scale in vivo CRISPR screens in CD8 T cells","volume":"178","author":"Dong","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2026.154003_bib67","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-019-1326-9","article-title":"TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection","volume":"571","author":"Alfei","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154003_bib68","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154003_bib69","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.cell.2018.10.024","article-title":"Genome-wide CRISPR screens in primary human T cells reveal key regulators of immune function","volume":"175","author":"Shifrut","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2026.154003_bib70","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/2159-8290.CD-22-1319","article-title":"Disruption of SUV39H1-Mediated H3K9 methylation sustains CAR T-cell function","volume":"14","author":"Jain","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbrc.2026.154003_bib71","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-Negative TGF-\u03b2 receptor enhances PSMA-Targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbrc.2026.154003_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512317","article-title":"CRISPR\/Cas9: a powerful strategy to improve CAR-T cell persistence","volume":"24","author":"Wei","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.154003_bib73","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-23-0677","article-title":"Knocking out CD70 rescues CD70-Specific NanoCAR T cells from antigen-induced exhaustion","volume":"12","author":"De Munter","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbrc.2026.154003_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1354825","article-title":"Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR\/Cas9 gene editing technology","volume":"15","author":"Tao","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.154003_bib75","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.cell.2015.04.029","article-title":"Regnase-1 and roquin regulate a common element in inflammatory mRNAs by spatiotemporally distinct mechanisms","volume":"161","author":"Mino","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2026.154003_bib76","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41586-019-1821-z","article-title":"Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy","volume":"576","author":"Wei","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154003_bib77","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154003_bib78","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s43018-021-00207-7","article-title":"Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients","volume":"2","author":"Biasco","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.bbrc.2026.154003_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110079","article-title":"CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia","volume":"37","author":"Zebley","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbrc.2026.154003_bib80","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbrc.2026.154003_bib81","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1126\/science.aae0491","article-title":"The epigenetic landscape of T cell exhaustion","volume":"354","author":"Sen","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2026.154003_bib82","article-title":"Epigenetic regulation of CD8(+) T cell exhaustion: recent advances and update","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.154003_bib83","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154003_bib84","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2026.154003_bib85","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1182\/bloodadvances.2024013044","article-title":"CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations","volume":"8","author":"Perna","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbrc.2026.154003_bib86","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1074\/jbc.AC119.007558","article-title":"Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators","volume":"294","author":"Sachdeva","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2026.154003_bib87","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1053\/j.seminhematol.2024.07.003","article-title":"Tuning CAR T-cell therapies for efficacy and reduced toxicity","volume":"61","author":"Blud","year":"2024","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bbrc.2026.154003_bib88","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.154003_bib89","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12015-019-09937-9","article-title":"Characterization of an Anti-CD5 directed CAR T-Cell against T-Cell malignancies","volume":"16","author":"Wada","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.bbrc.2026.154003_bib90","article-title":"Why reaching zero-dose children holds the key to achieving the sustainable development goals","volume":"11","author":"Hogan","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.bbrc.2026.154003_bib91","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2026.154003_bib92","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154003_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102010","article-title":"Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory non-hodgkin's lymphoma: a first-in-human phase I study","volume":"60","author":"Hu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.bbrc.2026.154003_bib94","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/s41375-023-01948-3","article-title":"Inserting EF1\u03b1-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection","volume":"37","author":"Jiang","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2026.154003_bib95","article-title":"CD38-Specific CAR integrated into CD38 locus driven by different promoters causes distinct antitumor activities of T and NK cells","volume":"10","author":"Liao","year":"2023","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.bbrc.2026.154003_bib96","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1016\/j.ymthe.2024.06.017","article-title":"Building a novel TRUCK by harnessing the endogenous IFN-gamma promoter for cytokine expression","volume":"32","author":"Ma","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbrc.2026.154003_bib97","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-025-09212-7","article-title":"Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery","volume":"644","author":"Chen","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154003_bib98","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s40364-023-00534-0","article-title":"Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges","volume":"11","author":"Pang","year":"2023","journal-title":"Biomark. Res."},{"key":"10.1016\/j.bbrc.2026.154003_bib99","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2017-05-787598","article-title":"CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells","volume":"131","author":"Legut","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.154003_bib100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2026.154003_bib101","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20211530","article-title":"High-efficiency nonviral CRISPR\/Cas9-mediated gene editing of human T cells using plasmid donor DNA","volume":"219","author":"Oh","year":"2022","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbrc.2026.154003_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102344","article-title":"CRISPR-Cas9-mediated homology-directed repair for precise gene editing","volume":"35","author":"Liao","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bbrc.2026.154003_bib103","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168571","article-title":"Approaches to enhance precise CRISPR\/Cas9-Mediated genome editing","volume":"22","author":"Denes","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.154003_bib104","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.tig.2025.04.014","article-title":"Optimizing homology-directed repair for gene editing: the potential of single-stranded DNA donors","volume":"41","author":"Jin","year":"2025","journal-title":"Trends Genet."},{"key":"10.1016\/j.bbrc.2026.154003_bib105","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s42003-025-08187-5","article-title":"Comparative analysis of multiple DNA double-strand break repair pathways in CRISPR-mediated endogenous tagging","volume":"8","author":"Tei","year":"2025","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bbrc.2026.154003_bib106","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.molcel.2021.12.026","article-title":"CRISPR-based genome editing through the lens of DNA repair","volume":"82","author":"Nambiar","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbrc.2026.154003_bib107","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \"Off-the-Shelf\" adoptive T-cell immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154003_bib108","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2025016927","article-title":"HLA-E single-chain trimer shields gene-edited allogeneic CAR T Cells from NK cell attack","author":"Apodaca","year":"2026","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbrc.2026.154003_bib109","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.cell.2014.09.029","article-title":"Genome-Scale CRISPR-Mediated control of gene repression and activation","volume":"159","author":"Gilbert","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2026.154003_bib110","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/nmeth.3630","article-title":"Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements","volume":"12","author":"Thakore","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.bbrc.2026.154003_bib111","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1093\/hmg\/ddac193","article-title":"High-throughput CRISPRi and CRISPRa technologies in 3D genome regulation for neuropsychiatric diseases","volume":"31","author":"Jones","year":"2022","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbrc.2026.154003_bib112","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1021\/acssynbio.3c00524","article-title":"Applications of CRISPR epigenome editors in tumor immunology and autoimmunity","volume":"13","author":"Yahsi","year":"2024","journal-title":"ACS Synth. Biol."},{"key":"10.1016\/j.bbrc.2026.154003_bib113","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nature14136","article-title":"Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex","volume":"517","author":"Konermann","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154003_bib114","doi-asserted-by":"crossref","first-page":"eabj4008","DOI":"10.1126\/science.abj4008","article-title":"CRISPR activation and interference screens decode stimulation responses in primary human T cells","volume":"375","author":"Schmidt","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2026.154003_bib115","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1038\/s41588-023-01554-0","article-title":"Transcriptional and epigenetic regulators of human CD8(+) T cell function identified through orthogonal CRISPR screens","volume":"55","author":"McCutcheon","year":"2023","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbrc.2026.154003_bib116","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12943-024-01987-z","article-title":"Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies","volume":"23","author":"Xiang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbrc.2026.154003_bib117","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2026.154003_bib118","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s40364-024-00701-x","article-title":"State of the art CRISPR-based strategies for cancer diagnostics and treatment","volume":"12","author":"Di Carlo","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.bbrc.2026.154003_bib119","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nbt.3199","article-title":"Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers","volume":"33","author":"Hilton","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbrc.2026.154003_bib120","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nmeth.3325","article-title":"Functional annotation of native enhancers with a Cas9-histone demethylase fusion","volume":"12","author":"Kearns","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.bbrc.2026.154003_bib121","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nbt.2647","article-title":"DNA targeting specificity of RNA-guided Cas9 nucleases","volume":"31","author":"Hsu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbrc.2026.154003_bib122","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1093\/nar\/gkw159","article-title":"Repurposing the CRISPR-Cas9 system for targeted DNA methylation","volume":"44","author":"Vojta","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrc.2026.154003_bib123","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41375-023-01966-1","article-title":"Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome","volume":"37","author":"Salz","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2026.154003_bib124","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-Edited CAR7 T cells for relapsed T-Cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2026.154003_bib125","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbrc.2026.154003_bib126","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1038\/s41467-019-13007-6","article-title":"Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors","volume":"10","author":"Webber","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154003_bib127","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2022015825","article-title":"Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL","volume":"140","author":"Diorio","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.154003_bib128","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1038\/s41375-021-01282-6","article-title":"Base-edited CAR T cells for combinational therapy against T cell malignancies","volume":"35","author":"Georgiadis","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2026.154003_bib129","doi-asserted-by":"crossref","first-page":"10303","DOI":"10.1182\/blood-2022-166432","article-title":"CTX110 allogeneic CRISPR-Cas9-Engineered CAR T cells in patients (Pts) with relapsed or refractory (R\/R) large B-Cell lymphoma (LBCL): results from the phase 1 dose escalation carbon Study","volume":"140","author":"McGuirk","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.154003_bib130","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-181869","article-title":"Multiplex prime editing and PASSIGE TM for non-viral generation of an allogeneic CAR-T cell product","volume":"142","author":"Pomeroy","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.154003_bib131","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1038\/s41587-022-01377-0","article-title":"Frequent aneuploidy in primary human T cells after CRISPR-Cas9 cleavage","volume":"40","author":"Nahmad","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbrc.2026.154003_bib132","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1388475","article-title":"Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review","volume":"14","author":"Moradi","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2026.154003_bib133","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003499","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types","volume":"9","author":"Kverneland","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbrc.2026.154003_bib134","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23270","article-title":"In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target","volume":"547","author":"Manguso","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154003_bib135","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ccell.2022.06.001","article-title":"Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence","volume":"40","author":"Belk","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2026.154003_bib136","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41586-025-09507-9","article-title":"Systematic discovery of CRISPR-boosted CAR T cell immunotherapies","volume":"646","author":"Datlinger","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154003_bib137","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1158\/2159-8290.CD-20-1243","article-title":"CRISPR screening of CAR T cells and cancer stem cells reveals critical dependencies for cell-based therapies","volume":"11","author":"Wang","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbrc.2026.154003_bib138","article-title":"660 A phase 1\/2 study of KSQ-001EX: an autologous tumor-infiltrating lymphocyte therapy engineered to inactivate the SOCS1 gene in patients with select advanced solid tumors","volume":"12","author":"Amaria","year":"2024","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.bbrc.2026.154003_bib139","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-021-01115-0","article-title":"T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors","volume":"14","author":"Tsimberidou","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2026.154003_bib140","volume":"vol. 13","author":"Hammer Mannering","year":"2025"},{"key":"10.1016\/j.bbrc.2026.154003_bib141","article-title":"569 A phase 1\/2 study of KSQ-004EX: autologous tumor infiltrating lymphocytes, engineered to inactivate genes encoding SOCS1 and regnase-1, in patients with select advanced solid tumors","volume":"13","author":"Amaria","year":"2025","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.bbrc.2026.154003_bib142","article-title":"A first-in-human study of CRISPR\/Cas9-engineered tumor infiltrating lymphocytes (TILs) product GT316 as monotherapy in advanced solid tumors","volume":"42","author":"Guo","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.154003_bib143","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(25)00083-X","article-title":"Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial","volume":"26","author":"Lou","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2026.154003_bib146","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1182\/bloodadvances.2021006232","article-title":"CRISPR\/Cas9 genome-edited universal CAR T cells in patients with relapsed\/refractory lymphoma","volume":"6","author":"Guo","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbrc.2026.154003_bib152","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz448","article-title":"Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer","volume":"30","author":"Lin","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbrc.2026.154003_bib151","article-title":"Phase I study of CRISPR-engineered CAR-T cells with PD-1 inactivation in treating mesothelin-positive solid tumors","volume":"38","author":"Wang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.154003_bib153","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/01.HS9.0000848712.54842.0a","article-title":"P1464: DECREASING HPK1 expression in CD19 car-t cells: a novel strategy to overcome challenges of cell therapy for adult (R\/R) B-all","volume":"6","author":"Zhang","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.bbrc.2026.154003_bib148","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-Engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for Relapsed\/Refractory B-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154003_bib150","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.bbrc.2026.154003_bib156","doi-asserted-by":"crossref","first-page":"eabq3010","DOI":"10.1126\/scitranslmed.abq3010","article-title":"Phase 1 clinical trial of CRISPR-Engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbrc.2026.154003_bib157","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/01.HS9.0000848676.15840.df","article-title":"P1455: first-in-human trial OF CB-010, a crispr-edited allogeneic ANTI-CD19 CAR -T cell therapy with a PD-1 KNOCK out, in patients with relapsed or refractory B cell NON-hodgkin lymphoma (antler study)","volume":"6","author":"Nastoupil","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.bbrc.2026.154003_bib158","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1280007","article-title":"Case report: differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma","volume":"14","author":"Mu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.154003_bib159","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-178723","article-title":"Phase 1\/2 Dose-Escalation\/Dose-Expansion Study of Anti-CD7 allogeneic CAR-T cells (WU-CART-007) in relapsed or refractory (R\/R) T-Cell acute lymphoblastic Leukemia\/lymphoblastic lymphoma (T-ALL\/LBL)","volume":"142","author":"Ghobadi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.154003_bib160","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/01.HS9.0000844368.41871.e3","article-title":"P370: early results OF a safety and efficacy study of allogeneic TRUUCAR\u2122 GC502 in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia (R\/R B-all)","volume":"6","author":"Li","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.bbrc.2026.154003_bib161","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-ND02","article-title":"Abstract ND02: CTX112 and CTX131: next-generation CRISPR\/Cas9-engineered allogeneic (allo) CAR T cells incorporating novel edits that increase potency and efficacy in the treatment of lymphoid and solid tumors","volume":"83","author":"Terrett","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154003_bib162","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2676","article-title":"A phase 1\/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9-engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors","volume":"42","author":"Pal","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.154003_bib163","article-title":"Phase I clinical trial of MUC1-targeted CAR-T cells with PD-1-knockout in the treatment of advanced breast cancer","volume":"42","author":"Lin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.154003_bib147","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-4095","article-title":"Preclinical characterization of switchable allogeneic chimeric antigen receptor T cells to support first in human clinical study in CD123-positive hematologic and lymphatic malignancies","volume":"83","author":"Ehninger","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154003_bib165","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1016\/j.cell.2025.07.046","article-title":"Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy","volume":"188","author":"Wu","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2026.154003_bib144","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40164-023-00457-4","article-title":"CRISPR\/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy","volume":"12","author":"Chen","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2026.154003_bib145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1401683","article-title":"Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR\/Cas9 editing and safety evaluation of the transcriptome","volume":"15","author":"Pavlovic","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.154003_bib149","article-title":"Immunotherapy for pediatric acute lymphoblastic leukemia: recent advances and future perspectives","volume":"13","author":"Lv","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.154003_bib154","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy485.002","article-title":"33OAnti-MUC1 CAR-T cells combined with PD-1 knockout engineered T cells for patients with non-small cell lung cancer (NSCLC): a pilot study","volume":"29","author":"Chen","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbrc.2026.154003_bib155","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","article-title":"Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer","volume":"21","author":"Wang","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbrc.2026.154003_bib164","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \"off-the-shelf\" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2026.154003_bib169","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-Targeted allogeneic CAR T-Cell therapy for advanced clear cell renal cell carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbrc.2026.154003_bib168","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(24)00508-4","article-title":"Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study","volume":"26","author":"Iyer","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2026.154003_bib171","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1182\/blood-2021-152985","article-title":"Clinical manufacture of FT819: use of a clonal multiplexed-engineered master induced pluripotent stem cell line to mass produce off-the-shelf CAR T-Cell therapy","volume":"138","author":"Yuan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.154003_bib173","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-153775","article-title":"Clinical-Scale production and characterization of Ntla-5001-a novel approach to manufacturing CRISPR\/Cas9 engineered T cell therapies","volume":"138","author":"Cossette","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.154003_bib166","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40364-024-00616-7","article-title":"Correction: crispr\/cas-based CAR-T cells: production and application","volume":"12","author":"Song","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.bbrc.2026.154003_bib167","doi-asserted-by":"crossref","first-page":"10303","DOI":"10.1182\/blood-2022-166432","article-title":"CTX110 allogeneic CRISPR-Cas9-Engineered CAR T cells in patients (Pts) with relapsed or refractory (R\/R) large B-Cell lymphoma (LBCL): results from the phase 1 dose escalation carbon Study","volume":"140","author":"McGuirk","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.154003_bib170","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-024-01568-z","article-title":"Advances in CAR-T-cell therapy in T-cell malignancies","volume":"17","author":"Zheng","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2026.154003_bib172","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-023-00482-9","article-title":"New cell sources for CAR-based immunotherapy","volume":"11","author":"Mazinani","year":"2023","journal-title":"Biomark. Res."},{"key":"10.1016\/j.bbrc.2026.154003_bib174","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.5966\/sctm.2014-0294","article-title":"Concise review: process development considerations for cell therapy","volume":"4","author":"Campbell","year":"2015","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.bbrc.2026.154003_bib175","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbrc.2026.154003_bib176","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2026.154003_bib177","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2026.154003_bib178","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1101\/gr.171322.113","article-title":"Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins","volume":"24","author":"Kim","year":"2014","journal-title":"Genome Res."},{"key":"10.1016\/j.bbrc.2026.154003_bib179","doi-asserted-by":"crossref","first-page":"10437","DOI":"10.1073\/pnas.1512503112","article-title":"Generation of knock-in primary human T cells using Cas9 ribonucleoproteins","volume":"112","author":"Schumann","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2026.154003_bib180","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.04766","article-title":"Enhanced homology-directed human genome engineering by controlled timing of CRISPR\/Cas9 delivery","volume":"3","author":"Lin","year":"2014","journal-title":"eLife"},{"key":"10.1016\/j.bbrc.2026.154003_bib181","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1038\/sj.gt.3302592","article-title":"Intracellular trafficking of nonviral vectors","volume":"12","author":"Medina-Kauwe","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.bbrc.2026.154003_bib182","doi-asserted-by":"crossref","first-page":"E10745","DOI":"10.1073\/pnas.1711979114","article-title":"Precision genome editing using synthesis-dependent repair of Cas9-induced DNA breaks","volume":"114","author":"Paix","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2026.154003_bib183","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jcyt.2024.03.011","article-title":"Interfacing data science with cell therapy manufacturing: where we are and where we need to be","volume":"26","author":"Wang","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbrc.2026.154003_bib184","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1158\/1078-0432.CCR-19-3845","article-title":"The outcome of Ex vivo TIL expansion is highly influenced by spatial heterogeneity of the tumor T-Cell repertoire and differences in intrinsic In vitro growth capacity between T-Cell clones","volume":"26","author":"Poschke","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154003_bib185","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12896-018-0419-0","article-title":"Optimized DNA electroporation for primary human T cell engineering","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.bbrc.2026.154003_bib186","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101635","article-title":"CRISPR\/methotrexate-integrated strategy for TCR-T cell engineering with reduced chromosome 14 loss","volume":"33","author":"Xu","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.bbrc.2026.154003_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102636","article-title":"Off-target effects in CRISPR-Cas genome editing for human therapeutics: progress and challenges","volume":"36","author":"Kalter","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bbrc.2026.154003_bib188","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41588-025-02428-3","article-title":"Measurement and clinical interpretation of CRISPR off-targets","volume":"58","author":"Angelini Stewart","year":"2026","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbrc.2026.154003_bib189","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41587-024-02307-y","article-title":"Tracking-seq reveals the heterogeneity of off-target effects in CRISPR-Cas9-mediated genome editing","volume":"43","author":"Zhu","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbrc.2026.154003_bib190","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR-Cas9 structures and mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu. Rev. Biophys."},{"key":"10.1016\/j.bbrc.2026.154003_bib191","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154003_bib192","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/s41467-019-12449-2","article-title":"High levels of AAV vector integration into CRISPR-induced DNA breaks","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154003_bib193","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1016\/j.ymthe.2024.09.032","article-title":"AAV vector-derived elements integrate into Cas9-generated double-strand breaks and disrupt gene transcription","volume":"32","author":"Bazick","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbrc.2026.154003_bib194","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41467-022-28244-5","article-title":"CRISPR-Cas9 induces large structural variants at on-target and off-target sites in vivo that segregate across generations","volume":"13","author":"Hoijer","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154003_bib195","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo7676","article-title":"Comprehensive analysis and accurate quantification of unintended large gene modifications induced by CRISPR-Cas9 gene editing","volume":"8","author":"Park","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbrc.2026.154003_bib196","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/s41467-022-28900-w","article-title":"Cas9 exo-endonuclease eliminates chromosomal translocations during genome editing","volume":"13","author":"Yin","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154003_bib197","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jmcb\/mjv016","article-title":"Efficient inversions and duplications of mammalian regulatory DNA elements and gene clusters by CRISPR\/Cas9","volume":"7","author":"Li","year":"2015","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.bbrc.2026.154003_bib198","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00439-023-02561-1","article-title":"Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells","volume":"142","author":"Hunt","year":"2023","journal-title":"Hum. Genet."},{"key":"10.1016\/j.bbrc.2026.154003_bib199","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nmeth.4278","article-title":"CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets","volume":"14","author":"Tsai","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.bbrc.2026.154003_bib200","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.aav9023","article-title":"Unbiased detection of CRISPR off-targets in vivo using DISCOVER-Seq","volume":"364","author":"Wienert","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2026.154003_bib201","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nbt.3583","article-title":"Analyzing CRISPR genome-editing experiments with CRISPResso","volume":"34","author":"Pinello","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbrc.2026.154003_bib202","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.stem.2021.02.002","article-title":"Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq","volume":"28","author":"Turchiano","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bbrc.2026.154003_bib203","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12864-018-4561-9","article-title":"UDiTaS, a genome editing detection method for indels and genome rearrangements","volume":"19","author":"Giannoukos","year":"2018","journal-title":"BMC Genom."},{"key":"10.1016\/j.bbrc.2026.154003_bib204","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41587-024-02171-w","article-title":"Genome engineering with Cas9 and AAV repair templates generates frequent concatemeric insertions of viral vectors","volume":"43","author":"Suchy","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbrc.2026.154003_bib205","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax2941","article-title":"Pervasive head-to-tail insertions of DNA templates mask desired CRISPR-Cas9-mediated genome editing events","volume":"6","author":"Skryabin","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbrc.2026.154003_bib206","doi-asserted-by":"crossref","DOI":"10.1038\/s44222-025-00360-z","article-title":"A clinical roadmap for base and prime editing","volume":"3","author":"Flugel","year":"2025","journal-title":"Nat. Rev. Bioeng."},{"key":"10.1016\/j.bbrc.2026.154003_bib207","article-title":"Safety-first TCR-T: AI-guided specificity, base-editing to prevent mispairing, and prioritizing public neoantigens","volume":"17","author":"Zhang","year":"2026","journal-title":"Front. Immunol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26007679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26007679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:59:16Z","timestamp":1780664356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26007679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":207,"alternative-id":["S0006291X26007679"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154003","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leveraging CRISPR\/Cas9 for optimized adoptive T cell therapies: From molecular engineering to clinical manufacturing","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"154003"}}